Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML.

作者信息

Popovici Cornel, Charbonnier Aude, Gisserot Olivier, Aguilon Philippe, Rémy Virginie, Olschwang Sylviane, Mozziconacci Marie-Joëlle

机构信息

Laboratoire d'Oncologie Moléculaire, INSERM UMR599 et Institut Paoli-Calmettes, Marseille, France.

出版信息

Leuk Res. 2008 Feb;32(2):361-2. doi: 10.1016/j.leukres.2007.03.001. Epub 2007 Apr 6.

DOI:10.1016/j.leukres.2007.03.001

PMID:17412419

Abstract

摘要

相似文献

Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML.

Leuk Res. 2008 Feb;32(2):361-2. doi: 10.1016/j.leukres.2007.03.001. Epub 2007 Apr 6.

E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib.E355G 突变出现在一名对伊马替尼耐药的 e19a2 慢性髓性白血病患者中。

J Clin Pathol. 2010 Aug;63(8):737-40. doi: 10.1136/jcp.2010.078311.

Dasatinib in chronic myelogenous leukemia.达沙替尼治疗慢性粒细胞白血病

N Engl J Med. 2006 Sep 7;355(10):1062-3; author reply 1063-4.

A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib.

Leukemia. 2006 Nov;20(11):2057-60. doi: 10.1038/sj.leu.2404400. Epub 2006 Sep 28.

Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib.在对伊马替尼耐药的患者的Ph+白血病细胞中发现D276G和L364I Bcr-Abl突变的证据。

Leukemia. 2005 Jan;19(1):132-4. doi: 10.1038/sj.leu.2403453.

Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.一名同时表达p190（BCR-ABL）癌蛋白和JAK2V617F突变的慢性髓性白血病患者对伊马替尼的反应

Leuk Res. 2010 Jan;34(1):e27-9. doi: 10.1016/j.leukres.2009.08.009. Epub 2009 Sep 12.

Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.伊马替尼可使具有e19a2 BCR-ABL转录本的急变期或干扰素治疗失败的慢性髓性白血病患者产生细胞遗传学反应。

Leukemia. 2004 Sep;18(9):1539-40. doi: 10.1038/sj.leu.2403454.

Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.伴有e19a2非典型转录本的慢性髓性白血病：早期伊马替尼耐药及对达沙替尼的完全缓解

Cancer Genet Cytogenet. 2010 Sep;201(2):133-4. doi: 10.1016/j.cancergencyto.2010.05.012.

BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.未接受过酪氨酸激酶抑制剂治疗和已暴露于酪氨酸激酶抑制剂的东南亚慢性髓性白血病患者的 BCR-ABL 激酶结构域突变。

Exp Mol Pathol. 2012 Apr;92(2):259-65. doi: 10.1016/j.yexmp.2012.01.007. Epub 2012 Jan 31.

Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.并非所有慢性粒细胞白血病中的伊马替尼耐药都是由BCR-ABL激酶结构域突变引起的。

Ann Hematol. 2006 Dec;85(12):841-7. doi: 10.1007/s00277-006-0171-8. Epub 2006 Sep 28.

引用本文的文献

The silent players: Atypical isoforms as biomarkers and therapeutic hurdles in CML pathogenesis (Review).沉默的参与者：非典型异构体在慢性粒细胞白血病发病机制中作为生物标志物和治疗障碍（综述）

Oncol Rep. 2025 Dec;54(6). doi: 10.3892/or.2025.8995. Epub 2025 Sep 26.

Rapid Evolution to Blast Crisis Associated with a Q252H ABL1 Kinase Domain Mutation in e19a2 BCR-ABL1 Chronic Myeloid Leukaemia.与e19a2 BCR-ABL1慢性髓性白血病中Q252H ABL1激酶结构域突变相关的急变期快速演变

Case Rep Hematol. 2013;2013:490740. doi: 10.1155/2013/490740. Epub 2013 Sep 16.

Chronic Myeloid Leukemia with e19a2 BCR-ABL1 Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring.伴有e19a2 BCR-ABL1转录本及显著血小板增多症的慢性髓性白血病：分子监测的作用

Case Rep Hematol. 2012;2012:458716. doi: 10.1155/2012/458716. Epub 2012 Jul 2.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验